Legend Biotech reported strong financial results for the fourth quarter and full year 2024, touting several wins for its market leading CAR-T in multiple myeloma, Carvykti.
Carvykti, jointly developed and commercialized with J&J’s Janssen Biotech, generated $963 million in sales in 2024, helping to treat over 5,000 clinical and commercial patients with multiple myeloma. There are now 102 U.S. hospitals certified to treat with Carvykti.
In the first quarter of 2025, Legend initiated commercial production of Carvykti at a Novartis CMO facility in New Jersey. Legend plans to begin clinical production at its facility Ghent, Belgium in the coming weeks and launch commercial production there later this year in order to better serve patients in Europe.
“…as we continue to work toward doubling Carvykti’s supply in 2025, we anticipate growth to be driven by capacity expansion in Belgium and in New Jersey,” said Legend CEO Ying Huang.
The European push comes as Spain's national health system, Sistema Nacional de Salud, approved reimbursement for Carvykti for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of treatment.
Carvykti holds the distinction of being the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.
First approved by the FDA in 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, Carvykti’s approval was expanded in 2024, allowing use in patients who have received at least one prior line of therapy.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!